Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer
Background and objective Erlotinib is a targeted drug for non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy, influencing factors and toxicity of erlotinib in patients with NSCLC. Methods Patients with NSCLC who had been previously treated with at least one course...
Main Authors: | Yilong WU, Zhen WANG, Chongrui XU, Jinji YANG, Qing ZHOU, Yujuan HUANG, Yisheng HUANG |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2009-05-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2009.05.019&path%5B%5D=821 |
Similar Items
-
The Impact of Smoking Status on the Efficacy of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer
by: Yilong WU, et al.
Published: (2009-12-01) -
Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer
by: Yunjian HUANG, et al.
Published: (2009-12-01) -
Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01) -
Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
by: Haiqing YUAN, et al.
Published: (2009-07-01) -
Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer and COPD
by: Huiling ZHANG, et al.
Published: (2009-12-01)